We retrospectively reviewed our experience with the fine-needle aspiration biopsy (FNAB) diagnosis of primary and recurrent lymphoma to assess the ability of cytomorphology with and without ancillary flow cytometry (FCM) lymphocytic leukemia, lymphoplasmacytic lymphoma, Burkitt's lymphoma, mantle cell lymphoma, and plasmacytoma (all 100%). Subclassification was poor in marginal-zone lymphoma (33%), and initially as well in diffuse large B-cell lymphoma (62%), but it improved on review (95%), as did subclassification of follicular lymphoma (77 to 100% on review). Hodgkin's disease was recognized as malignant in only 44% of the cases (7/16) and was classified as such based on morphology alone.This review of our early efforts to diagnose and subclassify lymphoma with FNAB and FCM indicates that although a diagnosis and proper subclassification of lymphoma can be made with certainty in the majority of cases, recurrent or primary, it requires close coordination of cytomorphology and immunophenotyping data, which often comes with close cooperation of cytopathologists and hematopathologists. A mere cytological diagnosis of positive for lymphoma is no longer acceptable if FNAB is to become an independent diagnostic tool for lymphoma.
versus diffuse) was considered essential for lymphoma classification (22) . Thus, a cytological diagnosis of "positive for lymphoma" has been generally acceptable because in recurrent lymphoma, this was sufficient for continued patient management, and in the case of a primary diagnosis, there was an expectation that an excisional biopsy would be performed for confirmation and subclassification. For FNAB to be accepted as an independent diagnostic test, however, this type of cytological diagnosis is not acceptable, because it does not provide sufficient information for clinicians to make therapeutic decisions (23) .
With advances in the understanding of the biology, immunology, and molecular genetics of lymphoma in the past two decades, lymphoid neoplasms are now defined by a combination of morphologic, immunophenotypic, genotypic features, and characteristic clinical presentations. Architectural patterns, which historically have been the gold standard for lymphoma subclassification, are no longer of paramount importance in many cases. As a result, it should now be possible to diagnose and classify lymphoma subtypes that have a characteristic cytomorphology and immunophenotype without examination of tissue sections (24, 25) .
Immunophenotyping is critical for lymphoma diagnosis and subclassification, particularly in the area of small-cell lymphomas, which have overlapping morphology both with reactive processes and with each other, making diagnosis and subclassification extremely difficult on cytomorphology alone (26 -29) . Immunophenotyping by flow cytometry (FCM) is a rapid and sensitive method to evaluate lymphoid markers (30) . It appears to be especially suitable for cytology specimens because it requires only a small sample, is suitable for cells already in suspension, and has a rapid turnaround time. FCM gives quantitative results and can detect small abnormal cell populations in a reactive background; it can also assess co-expression of antigens on subsets of cells and the relative density of surface antigens. Although immunocytochemistry allows a close correlation between immunophenotype and cytomorphology (1) (2) (3) (4) 31) , FCM has the advantage of being able to identify a small population of abnormal cells that may not be apparent on morphology alone. This feature significantly improves the diagnostic sensitivity and thus is particularly helpful for the diagnosis of small B-cell lymphomas. In addition, current techniques allow detection of intracytoplasmic antigens, further closing the gap between application of FCM and immunohistochemistry.
In our hospital, FNAB for the diagnosis of lymphoma has been done with increasing frequency, but the use of FCM as well as the stringency of the approach to lymphoma subclassification have not been uniform in the past. To evaluate the role of FCM and the feasibility for primary diagnosis and subclassification of lymphoma on FNAB, we undertook a retrospective review of our performance in this area. We retrospectively analyzed 139 consecutive cases of confirmed lymphoma during a period when FNAB was gradually adapted as a routine diagnostic tool to evaluate lymphoid lesions at our institution. Our aims were to assess the ability to diagnose lymphoma using a combination of FNAB/ FCM in nodal and extranodal sites, the ability to subclassify lymphoma with these techniques, the applicability of such an approach as an independent diagnostic test for the diagnosis of primary lymphoma, and the limitations of the technique.
MATERIALS AND METHODS

Case Selection
FNABs performed at the Massachusetts General Hospital during a 2-and-a-half-year period (January 1995 to July 1997) were reviewed retrospectively when FNAB was evolving as an independent diagnostic test for the diagnosis of lymphoma in our hospital. Cases were identified through a computer search of the department database for lymphoid lesions. These cases initially included all FNAB from lymph nodes and from various extranodal sites with a prominent lymphoid component on the smears. Many of the cases, particularly the extranodal sites, were performed for a mass not clinically suspected of being a lymphoma. Only 139 FNAB from 129 patients in whom a definitive diagnosis of lymphoma was ultimately made were chosen for this study, excluding benign and reactive lesions, as well as metastatic nonlymphoid malignancies. Aspirates with insufficient tissue for diagnosis were also excluded. The final diagnosis of lymphoma was made by a combination of cytology, flow cytometry immunophenotyping, surgical or core biopsy, and in certain recurrent cases, with clinical information alone. There were 95 patients corresponding to 102 FNAB who eventually had surgical biopsies done, either needle core or excisional biopsies. On 37 FNAB from 34 patients, a diagnosis of lymphoma (12 primary) was made by FNAB Ϯ FCM without a subsequent tissue biopsy.
Primary lymphoma was defined as a previously undiagnosed lymphoma in which the FNAB was the primary diagnostic test. Recurrent lymphoma was defined as one in which the diagnosis of lymphoma had been made by a previous biopsy procedure.
FNAB Specimen Processing
The FNAB specimens were obtained by either a cytopathologist or radiologist using a 22-25-gauge needle with multiple passes. Direct smears were made and stained with a rapid hematoxylin and eosin stain, a standard Papanicolaou stain, or an air-dried Romanowsky-type stain. It was routine to attempt to obtain aspirated tissue for FCM analysis on all FNAB that demonstrated a significant lymphoid component on the rapid interpretation smears. Usually, additional dedicated aspirates were performed solely to obtain cells for FCM. This was not accomplished or possible in all cases, however. In addition, some cases proved insufficient for FCM because of scant cellularity, cellular degeneration, and excessive peripheral blood contamination.
For deep-seated lesions in which lymphoma was detected on rapid interpretation, core biopsies were procured and sent to the frozen section lab as a back-up for immunohistochemistry, should the aspirate for flow cytometry be insufficient.
Diagnostic Data
To analyze our actual performance over this time interval, we used for this study the diagnoses issued in the cytopathology and flow cytometry reports. For all cases that were not subclassified on either report and for which a tissue biopsy had provided a definitive subclassification, the slides were retrieved and reviewed by MBP and HYD, together with the flow cytometry data, but without knowledge of the final diagnosis.
In all cases, cytopathologists performed the evaluation of the cytomorphology and issued the primary report; hematopathologists performed the evaluation of the flow-cytometric analysis and issued an addendum report on each case. Needle rinsings from each aspirate, and in most cases, dedicated aspirates just for needle rinsing in saline, were used for FCM analysis. When available on radiologically guided biopsies, tissue fragments from supplemental needle core biopsies were frozen for histologic and immunohistologic examination. During this time period, there was no standardized approach to the coordination of flow cytometry and cytomorphology for a final diagnosis, particularly with respect to subclassification. In rare cases, the cytopathology report was issued without knowledge of FCM results, for example, in obviously malignant cases when subclassification was not attempted, whereas in others, these results were known and necessary for defining clonality. The cytopathology reports used general headings of positive, suspicious, or negative for malignant lymphoma or were atypical with a descriptive diagnosis.
Flow Cytometry
All cytology specimens containing a dominant lymphoid component were submitted for FCM.
Cases with limited available tissue, those suspicious for Hodgkin's lymphoma, and some of the recurrent lymphomas were not submitted for FCM. Four-color flow-cytometric analysis was done according to standard procedures (30) on a FACScan (Becton-Dickenson, San Diego, CA), and data were analyzed with the Lysys software (BectonDickenson). The antibody panels routinely used included CD19, CD20, CD5, CD10, CD23, CD3, CD7, CD4, CD8, CD43, CD45, CD14, and antibodies to immunoglobulin light chains (kappa and lambda). In addition to analysis of surface antigens, cells were also permeabilized for intracytoplasmic staining of immunoglobulin light chains or CD3 when indicated. A diagnosis of lymphoma was made if there was a B-cell population with a restricted (monotypic) light chain, or a dominant T-cell population with aberrant phenotype or phenotypes (lack and/or abnormal distribution of one or more pan-T-cell antigens). An absolute kappa to lambda lightchain ratio of Ͼ6 or Ͻ0.3 was usually required. However, the final interpretation also depended on other abnormalities, such as B cells expressing dim CD20 or coexpressing CD10 or CD5. A case was considered suspicious for lymphoma if analysis detected a borderline light-chain excess or a small subset of monotypic B cells or abnormal T cells. A negative diagnosis was made if only polyclonal B cells and/or normal T cells were found. FCM from cases with too few cells for analysis or only necrotic material was excluded.
Definitions of Diagnosis and Classification Used
A case was classified as "positive for lymphoma" in this study only if a positive diagnosis was definitively made by either cytomorphology or FCM, or both. A specimen that was diagnosed as suspicious for lymphoma by both morphology and FCM remained suspicious rather than positive. All cases were classified according to the REAL/WHO lymphoma classification system (24, 25) . A case was considered to have been subclassified on FNAB when the final report indicated that the results were diagnostic of, or consistent with, a particular lymphoma subtype on either the cytology or FCM report. Cases signed out as "positive for lymphoma," "high-grade lymphoma," "low-grade lymphoma," or "small-cell lymphoma" were not considered to have been subclassified. Subclassification of Hodgkin's disease was not attempted.
RESULTS
One hundred thirty-nine FNAB from 129 patients were analyzed in this study, including 120 patients who had a single FNAB, 8 patients who had two FNAB and 1 patient who had three. In patients with more than one FNAB, the aspirates were all performed at different times and/or from different lesions. Nodal sites constituted 56% (78/139) and extranodal sites 44% (61/139), the majority of which were obtained from the head and neck region, some of which likely represent lymph nodes. FCM was successfully performed on 105 (76%) cases. Overall, there were 84 (60%) cases representing a primary diagnosis of malignant lymphoma and 55 (40%) cases of recurrent lymphoma.
The final results taken from cytology and/or flow cytometry reports are summarized in Table 1 . Of all cases, 67% (93/139) were diagnosed as "positive for lymphoma," 19% (27/139) were diagnosed as suspicious, and 9% (12/139) were considered atypical, warranting further evaluation and a subsequent biopsy. Overall, 5% (7/139) of cases were falsely negative. The positive rate was similar between cases of primary and recurrent lymphoma (66% versus 69%).
There were 105 (76%) cases with adequate tissue for FCM analysis. The overall positive rate for a diagnosis of lymphoma by FCM was 77% with a false negative rate of zero. Similarly, the positive rate for the diagnosis of primary lymphoma was 74%. Among five cases considered cytologically negative because of a polymorphous lymphoid component, one was monoclonal by FCM analysis and subsequently confirmed to be an extranodal marginal-zone B-cell lymphoma (MZL). In addition, 3 of 18 cytologically suspicious cases and 2 of 12 cytologically atypical cases were positive for lymphoma by FCM. There were 17 cases of lymphoma in which FCM was negative. Ten of these were Hodgkin's disease (HD). The others included one anaplastic large-cell lymphoma (ALCL), one follicle center lymphoma (FL), one MZL, two plasmacytomas, and two diffuse large B-cell lymphomas (DLBCL).
Accuracy of Diagnosis among Lymphoma Subtypes
Analysis of the different lymphoma subtypes showed variation in the frequency with which they were positively identified as lymphoma. Overall, the positive diagnosis rate was 100% for B-cell chronic lymphocytic leukemia/small lymphocytic lymphoma (B-CLL/SLL; 9/9), Burkitt's lymphoma (BL; 2/2), mantle cell lymphoma (MCL; 2/2), ALCL (2/2), and plasmacytoma (5/5; Table 2 ). Three of four cases of lymphoplasmacytic lymphoma (LPL; 75%), 26/34 cases of DLBCL (76%), 15/22 FL (68%), and 3/5 (60%) peripheral T-cell lymphoma (PTCL) were also recognized as lymphoma. However, only 7/15 MZL (47%) and 7/16 HD (44%) were identified by either morphology or FCM as malignant.
When only 105 cases with FCM are considered, 3/3 LPL (100%), 21/24 DLBCL (88%), 13/18 FL (72%), and 3/3 PTCL (100%) were recognized as lymphoma in addition to CLL/SLL, MCL and BL. For the B-cell lymphomas, the diagnosis rested on detecting monotypic immunoglobulin light-chain expression; the three PTCL were recognized as cytologically malignant T cells with or without aberrant T-cell antigen expression. However, even with FCM, only 7/15 (47%) MZL were initially recognized definitely as neoplastic, having a distinct monotypic population by FCM. Six additional cases had a small monotypic population or a slight light-chain excess, which was not felt to be diagnostic of malignancy, and they lacked sufficient cytologic atypia to be recognized as malignant on morphologic grounds alone. All were diagnosed as suspicious or atypical, leading to additional biopsies.
Subclassification of Lymphoma
Of the 93 cases diagnosed as positive for lymphoma, 55 were subclassified on the initial reports (59%; Table 2 ). On review of 15 of the 26 unclassified but potentially classifiable cases, 12 additional cases were subclassified (total, 72%). Excluding 23 "unclassifiable" cases (16% of total), which were excluded because of an inability to confirm the subtype on subsequent biopsy, the 68% initial accuracy was improved to 83% after review. When only classifiable cases with FCM were considered (excluding HD and ALCL for which FCM is not beneficial), the accuracy rate was 74% in the initial reports, increasing to 92% after review ( Table 2) .
The accuracy of subclassification varied among the subtypes. Among the non-Hodgkin's lymphomas, all cases of SLL/CLL (Fig. 1A, C) , LPL, MCL (Fig. 1B-C) , BL, plasmacytoma and PTCL, on which FCM was done, were correctly classified in the initial reports. FL was correctly classified initially in 10 of 15 cases (67%; Fig. 2A-C) ; on review, three additional cases with FCM were correctly subclassified (87% of all cases and 100% of cases with FCM). Two cases of FL without FCM could not be subclassified. One case each of MCL and plasmacytoma that lacked FCM and one case of ALCL (Fig. 3C ) with normal FCM findings were recognized as lymphoma but not subclassified. Of the 26 cases of DLBCL (Fig. 3A) , only 14 were classified on the initial report (54%); the remainder were diagnosed as lymphoma on the cytology report and recognized as a B-cell lymphoma on the FCM report. Slides were available for review in 9/12 of these unclassified DLBCL cases, and 7 could be correctly subclassified simply by commenting on the large-cell morphology and/or characters of forward light scatter, increasing the subclassification rate to 81%. Two contained an admixture of smaller cells and could not be confidently subclassified.
MZL (Fig. 3B ) proved most difficult to subclassify, with only one of seven (14%) cases subclassified on the initial report. Slides were available for review on only two of six unclassified cases; one of these could be subclassified on review, for an overall accuracy of 28%, or 33% considering only those cases with FCM.
Seven of 16 HD (Fig. 3D) were recognized as malignant, and all were correctly classified on cytomorphology alone. The remaining nine cases were considered either atypical or suspicious for HD but lacked diagnostic Reed-Sternberg cells, thus leading to subsequent biopsy.
In summary, of the 26 cases that were not subclassified on FNAB/FCM initially and for which a tissue biopsy had provided definitive classification, slides were available for review in 15 cases. These included 2/6 MZL, 9/12 DLBCL, and 3/5 FL and 1/1 plasmacytoma. Of these, 12 cases could be further subclassified using morphology and FCM data, including 1/2 MZL, 7 /9 DLBCL (large cells), 3/5 FL (CD10ϩ), and 1 anaplastic plasmacytoma (CD45Ϫ, CD38ϩ, CD56ϩ). One case of MZL could not be subclassified even with FCM, and two cases of DL-BCL had admixed small cells and could not be subclassified. For another two cases (one MCL, one ALCL), slides were not reviewed because of lack of FCM analysis, for they would be unlikely to be subclassified based on morphology alone.
There were 23 cases of NHL that were unclassifiable by cytology and FCM in the initial reports, only 12 of which were positive for lymphoma by morphology and/or FCM. Of these cases, 13 had no subsequent biopsy (all recurrent cases without available history of previous classification), and 10 had only a core biopsy, on which a definite subclassification was not possible. Many had very limited clinical information. Further analysis demonstrated that all 12 cases were composed of CD19ϩ, CD20ϩ B cells with variable cell size, 3 were CD10ϩ, and all were CD5Ϫ. Thus, it is plausible that they included three additional FL, and the reminder were likely to be DLBCL, FL (CD10Ϫ), or MZL (see discussion).
DISCUSSION
We have evaluated a series of 139 confirmed lymphomas diagnosed using FNAB with and without FCM immunophenotyping analysis, including 84 cases (60%) in which this represented the primary diagnosis of lymphoma. We compared our diagnostic accuracy for cases with FCM with that of all cases, evaluating both the ability to positively diagnose lymphoma and the frequency with which cases were accurately subclassified. For a small number of initially unclassified but potentially subclassifiable cases, the available slides and FCM data were reviewed and cases subclassified if possible.
The ability to recognize lymphoma by FNAB is well established (1-21) . However, controversy still remains that centers on the ability of FNAB to replace excisional biopsy for a primary diagnosis and subclassification of lymphoma. Cytomorphology coupled with FCM analysis provided a definitive diagnosis of lymphoma in 77% of the cases in our series (82% of non-Hodgkin's lymphomas). The accuracy rate was similar for primary and recurrent lymphomas. Without FCM, the accuracy rate was 67%, supporting the importance of immunophenotyping as an important adjunct to the cytological diagnosis and subclassification of lymphoma. Those cases with FCM not considered cytologically malignant were all either cytologically suspicious or atypical, leading to further evaluation or biopsy. As such, with the routine use of FCM for the evaluation of all lymphoid dominant lesions, our falsenegative rate was zero.
Our overall diagnostic rate is similar to those of previous studies (4 -10, 20) indicating that collectively, FNAB combined with FCM is applicable in routine practice to the diagnosis of lymphoma, both recurrent and primary tumors. Meda et al. (4) , in a recent series, found cytology and FCM able to correctly diagnose and subclassify lymphoma in 77% (158/206) of NHL, including 72% (86/119) of primary cases. They especially emphasized the importance of close coordination between morphology and immunophenotyping for accurate diagnosis and subclassification. The value of such a coordinated effort is illustrated by the improved overall subclassification rate in this series from 73 to 92% among positive cases.
Dunphy and Remos (8) reported their results of FNAB and FCM in 73 cases of clinically suspected lymphoma. A positive diagnosis was made in 36/45 (80%) of recurrent lymphoma cases and 10/14 (71%) of primary cases. Cases suspicious or equivocal for lymphoma, which would often comprise a significant portion of cases in practice, were not mentioned, and subclassification was not attempted in this series. Young et al. (9) recently reported their experience with 100 FNAB, most of which were combined with results of FCM. Of the 81 cases of confirmed lymphoma, 58 (72%) cases were diagnosed cytologically as positive, 18 (22%) as suspicious, and 5 (6%) as equivocal. Although the number of positive cases for each lymphoma subtype was listed, the feasibility of subclassification by FNAB/FCM was not discussed. Sneige et al. (7) reported on 220 FNAB, a majority of which had a lymphoma diagnosis before the FNAB. Among them, 173/220 (79%) were positively diagnosed as lymphoma by FNAB in conjunction with immunocytochemistry. Another 15 cases (7% of the total cases) were inconclusive, of which 14/15 were proven to be lymphoma on subsequent biopsies, and 23 benign lesions were interpreted as reactive. Like ours, none of these studies had any true false positive diagnoses.
One of the main limitations to FNAB as an independent diagnostic tool for lymphoma has been the inability to subclassify cases for directing appropriate therapy, given the reliance of previous classifications on architectural features. The REAL/WHO classification has incorporated new criteria independent of tissue architecture in the diagnosis and subclassification of lymphoma. Thus, diseases with characteristic immunophenotypes and/or cytomorphology should be classifiable with FNAB. We found that lymphoma subtypes with characteristic morphology and specific immunophenotypic profiles were in fact diagnosed and subclassified with high accuracy, including B-CLL/SLL, BL, MCL, LPL and plasmacytoma. For example: B-CLL/SLL is characterized by a monomorphic small lymphoid cell population with round nuclei, clumped chromatin, and occasional nucleoli that displays a B-cell phenotype (CD19/20 ϩ) co-expressed with CD5 and CD23 without CD10. Monotypic light-chain and CD20 expression are dim (Fig. 1, A, C) . Neoplastic cells in BL are medium sized, monomorphic cells with round nuclei, multiple nucleoli, and abundant basophilic vacuolated cytoplasm that are associated with tingible body macrophages, and they demonstrate an immunophenotype of CD19/ 20ϩ, CD43ϩ and CD10ϩ but are CD5Ϫ and TdTϪ. In contrast, most cases of FL are composed of CD10ϩ, CD43Ϫ small B cells in a reactive background (Fig. 3) . MCL is composed of a monotonous small lymphoid-cell population with irregular nuclear membranes, grooves, and inconspicuous nucleoli, with scant to no cytoplasm that displays a CD19/20ϩ, CD5ϩ, CD23Ϫ, and CD10Ϫ immunophenotype with moderate monotypic light chain and CD20 expression (Fig. 1, B-C) . LPL is characterized by a small lymphoid cell population with plasmacytoid differentiation of varying degrees. Although the immunophenotype is relatively nonspecific, detection of monotypic intracytoplasmic light chain is a common finding among these cases, and when combined with the cytomorphology, allows for proper subclassification. Plasmacytoma is a tumor generally characterized by readily recognized plasma cells that immunophenotypically express bright CD38 and a cytoplasmic monotypic light chain with absence of CD19 and CD45. However, occasional cases with a high-grade morphology can cause confusion with large cell/immunoblastic lymphoma, as in one of our cases. Not all subtypes of lymphomas exhibit specific features, thus, the challenge remains for the classification of tumors with nonspecific and/or overlapping features. We found that the initial cytopathology and/or FCM reports had accurately subclassified only 54% of DLBCL, 67% of FL, and 14% of MZL.
In cases of DLBCL, the malignant morphologic features are typically so apparent that FCM analysis is often not necessary for a confident morphological diagnosis of lymphoma. As such, anticipating a subsequent biopsy for confirmation and subclassification, many of our earlier cases were simply diagnosed as "positive for lymphoma." Thus, 26/34 cases (76%) of DLBCL were recognized as lymphoma with certainty on FNAB/FCM, but only 59% of these positive cases (14/26) were initially subclassified as DLBCL. The simple mention of the large-cell predominance on smears or the recognition of cell size as indicated by FCM light-scatter analysis improves the classification rate as evidenced by the improved subclassification rate of 81% (95% when only considering those cases with FCM) on review of 7/12 unclassified cases. Interestingly, it was largely recognition of cell size that allowed for subclassification of most of the 46 cases described by Meda et al. (4) (36/46 [76%] recognized as large-cell lymphoma). FCM analysis of DL-BCL in their series was polyclonal or falsely negative in 16 cases, mostly attributable to a limited sample for FCM analysis. We did not experience this with our cases. One potential pitfall we did encounter was the difficulty in the distinction of some cases from Grade 3 FL. There were three cases of proven DLBCL that were CD10ϩ, indicating a follicle center cell origin. Fortunately, a patient with either high-grade FL or DLBCL would be treated similarly.
MZL and FCL are two lymphomas with heterogeneous morphologic features. MZL is also characterized by a nonspecific immunophenotype. Thus, they were more difficult to subclassify than other lymphomas, even retrospectively. FL and MZL both have morphologic features that overlap with a benign reactive process (26 -28) , being composed of a variably mixed population of small atypical cells with irregular nuclei and rare large cells. Monocytoid B cells, the characteristic cell of MZL, with abundant clear cytoplasm, may not be easy to recognize on smears, especially on wet fixed tissue. In addition, the high content of reactive cells may impair detection of a monoclonal B-cell population. Although CD10 expression in a small B-cell lymphoma is likely to be specific for a diagnosis of FL, it is not positive in all cases and is reported to be positive on only about 60% of the cases by immunohistochemistry or 90% by FCM (4, 32-34) . Moreover, CD10 is also expressed on cells of BL and some cases of DLBCL, causing diagnostic difficulty in the distinction from Grade 2-3/3 FL.
Of a total of 22 FL cases in our series, only 15 (68%) could be diagnosed as lymphoma in initial reports. Among them, 10/15 (67%) were initially subclassified as FL because of expression of CD10. On review of three of the five initially unclassified cases, three additional were found to have CD10ϩ small B cells, improving the subclassification of FL in this series to 87%, or to 100% when considering only those cases with FCM.
MZL often lacks specific cytologic features, although in occasional cases, a prominent monocytoid appearance can be appreciated. Of 15 total cases of MZL, fewer than half were initially reported as lymphoma (6/15; 47%). On review, one additional case was classified as positive and subclassified as MZL. All seven positive cases of MZL had monotypic light-chain restriction, but only four were cytologically malignant. In addition, small monotypic populations were found in additional six cases of MZL by FCM. Even though these six cases did not completely fulfill the criteria required in this study for defining a positive diagnosis, they were highly suspicious for lymphoma and clearly warranted further evaluation. Our results are in agreement with other reports that MZL is difficult to diagnose and subclassify by FNAB even after extensive ancillary studies (26 -28) .
In summary, our retrospective analysis showed a relatively high diagnostic accuracy for FNAB in the diagnosis of primary and recurrent lymphoma (67%), which was substantially improved with the addition of flow cytometry (77%). We found that continued use of the traditional cytopathology diagnostic category of "positive for lymphoma" frequently obscured the correct subclassification of some lymphomas. This was particularly true for MZL and DLBCL, which may lack diagnostic immunophenotypes and require careful integration of cytomorphology and immunophenotype for correct subclassification. When we reviewed the original material, we were able to correctly subclassify 72% of the cases overall, and 77% of those with flow cytometry-an accuracy rate for primary diagnosis that certainly seems to validate the procedure and justify its use as a primary diagnostic tool with lymphomas. The two lymphomas with the lowest diagnostic accuracy were HD and MZL. Although HD could be correctly recognized as malignant and could be classified by cytomorphology alone in half the cases, flow cytometry was of no added value except in excluding non-Hodgkin's lymphoma. Because distinction between classical and lymphocyte predominance HD remains important in determining treatment and prognosis and often requires immunophenotyping, either immunocytochemistry on smears or open biopsies will be needed in most cases of HD. The diagnosis of MZL requires integration of cytomorphology, immunophenotype, and clinical features, and until the morphologic and clinical spectrum of this disease is better understood, many cases may continue to need open biopsies for diagnosis and classification.
An issue that was not dealt with in this study but that needs further consideration is the availability of material for cytogenetic or molecular genetic analysis for diagnosis and of archival material for correlative scientific studies. Although it is clear that immunophenotyping by either flow cytometry or immunocytochemistry is essential for the diagnosis of lymphoma on FNAB, cytogenetic studies are not considered routine in lymphoma diagnosis. Many lymphomas have characteristic cytogenetic abnormalities that can be important in diagnosis or prognosis, including SLL/CLL, MCL, MZL, FL, and BL. Material obtained by FNAB is ideal for routine cytogenetic studies, and consideration should be given to submitting needle rinsing for cytogenetic analysis or making additional smears for FISH analysis in cases in which a rapid interpretation suggests one of these lymphomas.
When open biopsies are performed for diagnosis, there is always an archive of paraffin-embedded tissue-and often frozen tissue-that can be used for diagnostic molecular genetic analysis, additional immunophenotyping, or research. One concern about the increasing use of FNAB for primary diagnosis and classification of lymphomas is the potential loss of archival tissue for research. This is particularly acute in the present era of emerging technologies of genomics and proteomics. Although many laboratories prepare additional smears that can be stored for future studies, the suitability of these for molecular genetic analysis is questionable. For academic centers with a commitment to diagnostic FNAB, consideration should be given to establishing banks of viably frozen cells. These could be used for diagnostic molecular genetic analysis should a definite diagnosis not be made on routine morphology and immunophenotyping and could also serve as an archive of material for future immunophenotyping and genetic studies.
